Literature DB >> 21282420

Frequency of voriconazole resistance in vitro among Spanish clinical isolates of Candida spp. According to breakpoints established by the Antifungal Subcommittee of the European Committee on Antimicrobial Susceptibility Testing.

M Cuenca-Estrella1, A Gomez-Lopez, I Cuesta, O Zaragoza, E Mellado, J L Rodriguez-Tudela.   

Abstract

A total of 4,226 Spanish clinical isolates of Candida spp. were analyzed to assess resistance to voriconazole according to breakpoints established by the European Committee for Antimicrobial Susceptibility Testing (where susceptibility [S] to voriconazole corresponds to a MIC of ≤ 0.12 mg/liter). Resistance was uncommon among Candida albicans (5%), C. parapsilosis (1.2%), and C. tropicalis (11%) isolates. Voriconazole MICs of >0.12 mg/liter were more frequent among Candida glabrata and C. krusei isolates. A significant percentage of voriconazole-resistant strains came from oropharyngeal infections and exhibited high MICs of other azoles.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21282420      PMCID： PMC3067132          DOI： 10.1128/AAC.01757-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

1.  European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteria.

Authors:  Gunnar Kahlmeter; Derek F J Brown; Fred W Goldstein; Alasdair P MacGowan; Johan W Mouton; Anders Osterlund; Arne Rodloff; Martin Steinbakk; Pavla Urbaskova; Alkiviadis Vatopoulos
Journal:  J Antimicrob Chemother       Date:  2003-07-01       Impact factor: 5.790

2.  European Committee on Antimicrobial Susceptibility Testing (EUCAST) Technical Notes on antimicrobial susceptibility testing.

Authors:  G Kahlmeter; D F J Brown; F W Goldstein; A P MacGowan; J W Mouton; I Odenholt; A Rodloff; C-J Soussy; M Steinbakk; F Soriano; O Stetsiouk
Journal:  Clin Microbiol Infect       Date:  2006-06       Impact factor: 8.067

Review 3.  Epidemiology of invasive candidiasis: a persistent public health problem.

Authors:  M A Pfaller; D J Diekema
Journal:  Clin Microbiol Rev       Date:  2007-01       Impact factor: 26.132

4.  In vitro susceptibilities of bloodstream isolates of Candida species to six antifungal agents: results from a population-based active surveillance programme, Barcelona, Spain, 2002-2003.

Authors:  Manuel Cuenca-Estrella; Dolores Rodriguez; Benito Almirante; Juliette Morgan; Ana Maria Planes; Manel Almela; José Mensa; Ferran Sanchez; Josefina Ayats; Montserrat Gimenez; Margarita Salvado; David W Warnock; Albert Pahissa; Juan L Rodriguez-Tudela
Journal:  J Antimicrob Chemother       Date:  2004-12-23       Impact factor: 5.790

5.  Correlation of MIC with outcome for Candida species tested against voriconazole: analysis and proposal for interpretive breakpoints.

Authors:  M A Pfaller; D J Diekema; J H Rex; A Espinel-Ingroff; E M Johnson; D Andes; V Chaturvedi; M A Ghannoum; F C Odds; M G Rinaldi; D J Sheehan; P Troke; T J Walsh; D W Warnock
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

6.  EUCAST technical note on fluconazole.

Authors: 
Journal:  Clin Microbiol Infect       Date:  2007-12-05       Impact factor: 8.067

Review 7.  Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods.

Authors:  M A Pfaller; D Andes; D J Diekema; A Espinel-Ingroff; D Sheehan
Journal:  Drug Resist Updat       Date:  2010-11-02       Impact factor: 18.500

8.  Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial.

Authors:  B J Kullberg; J D Sobel; M Ruhnke; P G Pappas; C Viscoli; J H Rex; J D Cleary; E Rubinstein; L W P Church; J M Brown; H T Schlamm; I T Oborska; F Hilton; M R Hodges
Journal:  Lancet       Date:  2005 Oct 22-28       Impact factor: 79.321

9.  Head-to-head comparison of the activities of currently available antifungal agents against 3,378 Spanish clinical isolates of yeasts and filamentous fungi.

Authors:  Manuel Cuenca-Estrella; Alicia Gomez-Lopez; Emilia Mellado; Maria J Buitrago; Araceli Monzon; Juan Luis Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

10.  Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes.

Authors:  Andres Pascual; Thierry Calandra; Saskia Bolay; Thierry Buclin; Jacques Bille; Oscar Marchetti
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079
View more
  8 in total

1.  Distribution and antifungal susceptibility of yeasts isolates from intensive care unit patients.

Authors:  Vladimír Hrabovský; Victoria Takáčová; Eva Schréterová; Lydia Pastvová; Zuzana Hrabovská; Katarina Čurová; Leonard Siegfried
Journal:  Folia Microbiol (Praha)       Date:  2017-03-30       Impact factor: 2.099

2.  High prevalence of antibiotic resistance in commensal Escherichia coli among children in rural Vietnam.

Authors:  Oliver James Dyar; Nguyen Quynh Hoa; Nguyen V Trung; Ho D Phuc; Mattias Larsson; Nguyen T K Chuc; Cecilia Stålsby Lundborg
Journal:  BMC Infect Dis       Date:  2012-04-18       Impact factor: 3.090

3.  Nosocomial bloodstream Candida infections in a tertiary-care hospital in South Brazil: a 4-year survey.

Authors:  Viviane Gevezier da Costa; Regina Mariuza Borsato Quesada; Aline Tancler Stipp Abe; Luciana Furlaneto-Maia; Márcia Cristina Furlaneto
Journal:  Mycopathologia       Date:  2014-08-08       Impact factor: 2.574

4.  Epidemiology of invasive fungal infections in the mediterranean area.

Authors:  Ulrike Binder; Cornelia Lass-Flörl
Journal:  Mediterr J Hematol Infect Dis       Date:  2011-03-31       Impact factor: 2.576

5.  The susceptibility patterns of Candida species isolated from urine samples to posaconazole and caspofungin.

Authors:  Ali Zarei Mahmoudabadi; Ali Rezaei-Matehkolaei; Fataemeh Ghanavati
Journal:  Jundishapur J Microbiol       Date:  2015-03-21       Impact factor: 0.747

6.  D-Cateslytin: a new antifungal agent for the treatment of oral Candida albicans associated infections.

Authors:  Pauline Dartevelle; Claire Ehlinger; Abdurraouf Zaet; Christian Boehler; Morgane Rabineau; Benoit Westermann; Jean-Marc Strub; Sarah Cianferani; Youssef Haïkel; Marie-Hélène Metz-Boutigue; Céline Marban
Journal:  Sci Rep       Date:  2018-06-18       Impact factor: 4.379

7.  Investigating antibiotic resistance in non-clinical environments.

Authors:  Fiona Walsh
Journal:  Front Microbiol       Date:  2013-02-15       Impact factor: 5.640

8.  Antifungal susceptibility testing of Candida species isolated from the immunocompromised patients admitted to ten university hospitals in Iran: comparison of colonizing and infecting isolates.

Authors:  Parisa Badiee; Hamid Badali; Teun Boekhout; Kambiz Diba; Abdolkarim Ghadimi Moghadam; Ali Hossaini Nasab; Hadis Jafarian; Rasoul Mohammadi; Hossein Mirhendi; Mohammad Javad Najafzadeh; Ahmad Shamsizadeh; Jafar Soltani
Journal:  BMC Infect Dis       Date:  2017-11-21       Impact factor: 3.090
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.